fda gsk - Search News

Order byBest matchMost fresh

News

GSK shares fall

· 15h · on MSN

GSK shares fall after blood cancer drug likely headed for U.S. rejection

(Reuters) -GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects. The British drugmaker was trying to revive the drug,

Continue reading

GSK blood cancer drug fails to win backing of key US regulatory panel

· 10h · on MSN

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

6h

GSK’s Blenrep faces setback as FDA cancer committee votes against approval

Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab mafodotin) ...

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

4hon MSN

BofA Maintains a Sell Rating on GSK plc (GSK), Sets a PT of p1,510

The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results